By engineering hypoxia-driven circuits in EcN to release STING agonists, and harnessing the natural activation of pattern-recognition receptors, Leventhal et al. increased the production of interferons around tumours, which increased anti-tumour immunity (Leventhal et al., 2020). Here, STING1 is linked to neoplasm.